Glax­o­SmithK­line drops out of Ebo­la vac­cine de­vel­op­ment as R&D shifts re­sources to fran­chise drugs

GSK’s R&D or­ga­ni­za­tion has a new set of pri­or­i­ties — which doesn’t in­clude Ebo­la vac­cines.

The phar­ma gi­ant has hand­ed over ex­per­i­men­tal vac­cines for two va­ri­eties of Ebo­la as well as the Mar­burg virus that they were forced to shelve af­ter the last big out­break in Africa ran its course from 2014 to 2016.

The Sabin Vac­cine In­sti­tute will now take over the work as a new out­break spurs head­lines around the world. GSK is do­ing the han­dover for free; no mon­ey is ex­chang­ing hands. And the NIH’s vac­cine re­search group is step­ping in to part­ner on the de­vel­op­ment work — shoul­der­ing much of the cost.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER